202. Smith-Magenis syndrome
10 clinical trials,   10 drugs   (DrugBank: 4 drugs),   4 drug target genes,   6 drug target pathways

Searched query = "Smith-Magenis syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03492970
(ClinicalTrials.gov)
March 7, 20181/3/2018Melatonin in Adults With SMSCharacterization of Behavioral Disorders and 24 H-melatonin Level in Adults With Smith Magenis SyndromeSmith Magenis SyndromeBiological: Hourly dosing of the nychtemeral secretion of melatoninHôpital le VinatierHospices Civils de LyonCompleted18 Years65 YearsAll10N/AFrance
2NCT00506259
(ClinicalTrials.gov)
July 17, 200721/7/2007Treatment Strategies for Children With Smith-Magenis SyndromeA Phase One Treatment Trial of the Circadian Sleep Disturbance in Smith-Magenis Syndrome (SMS)Developmental Delay Disorders;Chromosome Deletion;Mental Retardation;Sleep Disorders, Circadian Rhythm;Self Injurious BehaviorDrug: dTR Melatonin (NIH CC PDS);Device: Phototherapy (Bright Light);Drug: Melatonin CRNational Human Genome Research Institute (NHGRI)NULLCompleted3 Years45 YearsAll23Phase 1United States
3NCT00691574
(ClinicalTrials.gov)
September 199830/5/2008Melatonin Levels in Smith Magenis Syndrome (SMS)Melatonin Levels in Sleep-disordered Smith-Magenis Syndrome: a Pilot StudyChromosome DisordersDietary Supplement: Melatonin;Device: Enviro-light artificial light boxOregon Health and Science UniversityNULLTerminated3 Years85 YearsAll5N/AUnited States